Primary care for you and your family, close to home.
Wellstar offers monoclonal antibody (MAB) infusions for eligible high-risk patients to help fight COVID-19.
Monoclonal antibody therapy is administered by IV infusion. The antibodies in the treatment mimic your body’s natural response to COVID-19, helping to boost your immune system. This can help stop the virus from entering your cells, limiting the spread of infection and preventing your symptoms from progressing.
Wellstar is working with the state and other resources to expand access to critical monoclonal antibody (mAb) therapy in our hospitals and health parks.
Patients can visit a Wellstar Urgent Care Center for evaluation. You must have a verified positive COVID-19 test to receive this treatment.
Once you have been evaluated as a candidate for mAb treatment by a Wellstar physician, a Wellstar team member will reach out to you to schedule an infusion appointment.
Based on evaluation, potential candidates for mAb include COVID-19 positive adults and pediatric patients (age 12–17 years and weighing at least 40 kg) who meet the following criteria for higher-risk progression to severe COVID-19:
For more information and health tips, visit our COVID-19 resource center.